Home
BIAF
BIAF News

Latest bioAffinity Technologies Inc. (BIAF) News on April 24, 2025

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Business Wire

7 days ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

ACCESS Newswire

7 days ago

ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

Zacks

17 days ago

BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

22 days ago

bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Business Wire

24 days ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

ACCESS Newswire

a month ago

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Business Wire

a month ago

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Business Wire

a month ago

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Business Wire

a month ago

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Business Wire

2 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

MT Newswires

2 months ago

bioAffinity Technologies Raises $1.4 Million After Warrant Exercise

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

PR Newswire

2 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Business Wire

2 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

PR Newswire

2 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Business Wire

2 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Zacks

3 months ago

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity

Zacks

3 months ago

The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity

Top Research Reports for Amazon.com, Bank of America & Caterpillar

Zacks

3 months ago

Top Research Reports for Amazon.com, Bank of America & Caterpillar

MT Newswires

3 months ago

BioAffinity Technologies Says Australian Patent Office Accepts Lung Cancer Test Application

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Business Wire

3 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Business Wire

3 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

3 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Boosts Sales with CyPath Lung

TipRanks

4 months ago

bioAffinity Technologies Boosts Sales with CyPath Lung

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

Business Wire

4 months ago

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Business Wire

4 months ago

bioAffinity Technologies Set for Continued Expansion in 2025

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

Business Wire

5 months ago

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Business Wire

5 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Business Wire

6 months ago

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

MT Newswires

6 months ago

bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

Business Wire

6 months ago

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

PR Newswire

6 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

Business Wire

6 months ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

PR Newswire

6 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

Business Wire

6 months ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

Business Wire

6 months ago

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

MT Newswires

6 months ago

BioAffinity Technologies Appoints J. Michael Edwards as CFO

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Business Wire

6 months ago

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Business Wire

6 months ago

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Business Wire

7 months ago

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

Business Wire

8 months ago

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

Business Wire

8 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

MT Newswires

9 months ago

BioAffinity Raises Nearly $1.8 Million From Offerings

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Business Wire

9 months ago

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

PR Newswire

9 months ago

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Business Wire

9 months ago

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

9 months ago

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

Business Wire

9 months ago

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

10 months ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

Business Wire

10 months ago

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

Business Wire

a year ago

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

bioAffinity Technologies News Update

Business Wire

a year ago

bioAffinity Technologies News Update

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

Business Wire

a year ago

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

Business Wire

a year ago

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire

a year ago

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

PR Newswire

a year ago

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Business Wire

a year ago

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

PR Newswire

a year ago

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

Business Wire

a year ago

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Business Wire

a year ago

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Here's Why We're A Bit Worried About bioAffinity Technologies' (NASDAQ:BIAF) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're A Bit Worried About bioAffinity Technologies' (NASDAQ:BIAF) Cash Burn Situation

bioAffinity Technologies News Update

Business Wire

a year ago

bioAffinity Technologies News Update

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

Business Wire

a year ago

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

bioAffinity Technologies In The News

Business Wire

a year ago

bioAffinity Technologies In The News

BM Technologies (BMTX) Champions Campus Excellence and Announces 2023 ACE Award and Partnership Winners

ACCESSWIRE

a year ago

BM Technologies (BMTX) Champions Campus Excellence and Announces 2023 ACE Award and Partnership Winners

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

GlobeNewswire

a year ago

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Business Wire

a year ago

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

Orion (OESX) Preliminary Q3 Results Depict Strong Demand

Zacks

a year ago

Orion (OESX) Preliminary Q3 Results Depict Strong Demand

MAIA Soars 20% on Interim Results From Lung Cancer Study

Zacks

a year ago

MAIA Soars 20% on Interim Results From Lung Cancer Study

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

Business Wire

a year ago

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

Simply Wall St.

a year ago

Glen Burnie Bancorp's (NASDAQ:GLBZ) Dividend Will Be $0.10

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

GlobeNewswire

a year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

The Container Store lowers Q3 sales guidance

Retail Dive

a year ago

The Container Store lowers Q3 sales guidance

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

a year ago

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

GlobeNewswire

a year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

3 Penny Stocks to Make You the Millionaire Next Door: 2024 Edition

InvestorPlace

a year ago

3 Penny Stocks to Make You the Millionaire Next Door: 2024 Edition

Pacira Appoints Frank D. Lee as Chief Executive Officer

GlobeNewswire

a year ago

Pacira Appoints Frank D. Lee as Chief Executive Officer

Innovative Solutions and Support Inc (ISSC) Reports Strong Q4 and Full Year Fiscal 2023 Results

GuruFocus.com

a year ago

Innovative Solutions and Support Inc (ISSC) Reports Strong Q4 and Full Year Fiscal 2023 Results

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

GlobeNewswire

a year ago

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

GlobeNewswire

a year ago

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Pleasing Signs As A Number Of Insiders Buy GeneDx Holdings Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy GeneDx Holdings Stock

Kustom Entertainment Inc. and Clover Leaf Capital Corp. Amend the Lock-Up Agreement in their Proposed Business Combination

GlobeNewswire

a year ago

Kustom Entertainment Inc. and Clover Leaf Capital Corp. Amend the Lock-Up Agreement in their Proposed Business Combination

Moolec Science to Host First Quarter Fiscal Year 2024 Business Update Conference Call

ACCESSWIRE

a year ago

Moolec Science to Host First Quarter Fiscal Year 2024 Business Update Conference Call

Lead Real Estate Co., Ltd Announces Sale of 17-unit Luxury Condominium in Tokyo

GlobeNewswire

a year ago

Lead Real Estate Co., Ltd Announces Sale of 17-unit Luxury Condominium in Tokyo

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Business Wire

a year ago

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

GlobeNewswire

a year ago

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

GlobeNewswire

a year ago

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)

Zacks

a year ago

Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)

ACCESSWIRE

a year ago

Vivakor Reports 39% Revenue Growth to $16.3 Million Revenue for Third Quarter 2023

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

Business Wire

a year ago

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Business Wire

a year ago

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Old Point Financial Corporation Declares Quarterly Dividend

PR Newswire

a year ago

Old Point Financial Corporation Declares Quarterly Dividend

Lead Real Estate Co., Ltd Reports Fiscal 2023 Year-end Financial Results

GlobeNewswire

a year ago

Lead Real Estate Co., Ltd Reports Fiscal 2023 Year-end Financial Results

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

GlobeNewswire

a year ago

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

PR Newswire

a year ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

ACCESSWIRE

a year ago

Vivakor Announces Results of Special Meeting of Shareholders with All Proposals Approved with Greater than 90% Voted For Each Proposal

Farmer Bros (NASDAQ:FARM) investors are sitting on a loss of 89% if they invested five years ago

Simply Wall St.

a year ago

Farmer Bros (NASDAQ:FARM) investors are sitting on a loss of 89% if they invested five years ago

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

Business Wire

a year ago

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire

a year ago

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks

a year ago

Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%

Simply Wall St.

a year ago

Individual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%

Share on Social Networks: